Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women

Conditions: Healthy Interventions: Drug: Letrozole LEBE 75 mg; Drug: Letrozole LEBE 150 mg; Drug: Letrozole LEBE 225 mg Sponsors: Rovi Pharmaceuticals Laboratories Recruiting

https://clinicaltrials.gov/study/NCT06315205

Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials

More News: Men | Menopause | Research | Women